(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/245199 A1

(51) International Patent Classification:
A61K 47/55 (2017.01) *A61P 3/04* (2006.01)
A61K 47/64 (2017.01) *A61P 1/16* (2006.01)
A61P 3/10 (2006.01)

(21) International Application Number:
PCT/EP2021/064930

(22) International Filing Date:
03 June 2021 (03.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20178057.4 03 June 2020 (03.06.2020) EP

(71) Applicant: **KØBENHAVNS UNIVERSITET** [DK/DK]; Nørregade 10, Copenhagen K, 1165 (DK).

(72) Inventors: **CLEMMENSEN, Christoffer**; c/o Københavns Universitet, Nørregade 10, 1165 Copenhagen K (DK). **KLEIN, Anders Bue**; c/o Københavns Universitet, Nørregade 10, 1165 Copenhagen K (DK). **PETERSEN, Jonas Odgaard**; c/o Københavns Universitet, Nørregade 10, 1165 Copenhagen K (DK). **FRØLUND, Bente Flensborg**; c/o Københavns Universitet, Nørregade 10, 1165 Copenhagen K (DK). **STRØMGAARD, Kristian**; c/o Københavns Universitet, Nørregade 10, 1165 Copenhagen K (DK).

(74) Agent: **AWA DENMARK A/S**; Strandgade 56, 1401 Copenhagen K (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: GLP1R AGONIST NMDAR ANTAGONIST CONJUGATES

(57) Abstract: The present invention relates to a conjugated molecule comprising a peptide displaying at least 0.1% activity of native glucagon-like peptide 1 (GLP-1) at the GLP-1 receptor, and an *N*-methyl-D-aspartate receptor (NMDAR) antagonist, the peptide being covalently bonded to the NMDAR antagonist either directly or through a chemical linker, the conjugated molecule for use in therapy, a pharmaceutical composition comprising the conjugated molecule, a method of reducing body weight of a mammal comprising administering the conjugated molecule to the mammal, and a non-therapeutic method of reducing body weight of a mammal comprising orally administering the conjugated molecule to the mammal.

WO 2021/245199 A1